Cardiome Pharma Corp. (COM.TO) Reports First Quarter Results
5/13/2013 7:51:50 AM
More...
|
Cardiome Pharma Corp. (COM.TO) to Present at Bloom Burton & Co. Healthcare Investor Conference
5/10/2013 7:19:33 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings From Merck & Co., Inc. (MRK)
5/2/2013 11:26:53 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Announces the Addition of Dr. Steen Juul-Möller as Medical Director, Europe
3/28/2013 6:55:25 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Named William Hunter as CEO
3/27/2013 10:03:24 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Reports Fourth Quarter and Full Year 2012 Financial Results
3/15/2013 8:12:01 AM
More...
|
Cardiome Pharma Corp. (COM.TO) to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 15
3/12/2013 12:13:36 PM
More...
|
Cardiome Pharma Corp. (COM.TO) Announces Settlement of Debt and Termination of Line of Credit With Merck & Co., Inc. (MRK)
3/4/2013 10:01:38 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Selects Quintiles to Manage Global Regulatory Affairs and Life Cycle Safety Activities for BRINAVESS™ (Vernakalant Intravenous)
2/5/2013 9:04:44 AM
More...
|
Cardiome Pharma Corp. (COM.TO) Enters Debt Settlement With Merck & Co., Inc. (MRK); Will Pay $20 Million
12/11/2012 7:52:05 AM
More...
|
|